Zhang Financial LLC Has $4.90 Million Stock Position in Amgen Inc. $AMGN

Zhang Financial LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 17,358 shares of the medical research company’s stock after purchasing an additional 1,424 shares during the period. Zhang Financial LLC’s holdings in Amgen were worth $4,899,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Legacy Investment Solutions LLC bought a new position in Amgen in the second quarter valued at about $27,000. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen during the second quarter worth $32,000. Howard Hughes Medical Institute bought a new stake in shares of Amgen in the 2nd quarter valued at about $32,000. Quaker Wealth Management LLC increased its position in Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares during the period. Finally, Cloud Capital Management LLC bought a new position in Amgen during the third quarter worth $34,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $382.87 on Wednesday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The stock has a market cap of $206.39 billion, a price-to-earnings ratio of 26.91, a P/E/G ratio of 3.76 and a beta of 0.46. The stock’s 50-day moving average is $345.41 and its 200 day moving average is $317.87. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the firm posted $5.31 earnings per share. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Truist Financial increased their target price on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Mizuho raised their target price on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Finally, Daiwa Securities Group upped their price target on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average target price of $351.76.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.